Abstract: The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein Ra, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections.

Abstract: The invention relates to a method for producing liquid fuel having a high alkane content and a low oxygenized compound content, said method comprising at least: a first step of treating 2-methylfuran with a catalyst and water in reaction conditions in order to form a mixture of products with at least ten carbon atoms; and a second step of catalytic hydrogenation and dehydration of the product or the mixture obtained in step 1, using suitable hydrogenation and dehydration catalysts.

Abstract: The invention relates to methods for increasing total lysine content in plants and plant products and related uses.

Abstract: The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the peroxisome proliferator-activated receptors (PPAR) and which, therefore, modulate the actions regulated by said receptors, such as inducing satiety, controlling ingestion and modulating metabolic effects, and thus are useful for the administration thereof as a pharmacological tool and as drugs for the treatment and/or prevention of metabolic diseases and cardiovascular diseases.

Abstract: A device and method for the hardware detection of local edges in an image, comprised of a plurality of elemental cells for mixed signal processing, locally interconnected with each other, comprising in each cell a first switch configured to enable the pre-charging of a condenser at the supply voltage; and where once said condenser is pre-charged, it discharges via a second switch connected to a power source which varies in a monotonically increasing manner with the analog voltage representing the value of the pixel concerned; and where the value of the pixel is compared asynchronously with the neighboring pixels of the neighboring cells via two inverters, a digital NOR gate, a digital NAND gate, a third and fourth switch and a memory feature to store the result.

Abstract: The present invention relates to a method for the detection and/or quantification of Streptococcus pneumoniae, a Gram-positive bacteria that is an important human pathogen, in an isolated biological sample, through magneto-amperometric biosensors, comprising detecting fragments of lytA gene of the microorganism, amplified through PCR, preferably asymmetric PCR or direct asymmetric PCR, by hybridization thereof to a specific probe fully complementary to a region of the amplified fragment. Furthermore, the present invention also relates to the use of primers SEQ ID NO: 3 and 4 together with probes SEQ ID NO: 1 and/or SEQ ID NO: 2 to perform the detection. The biosensor developed to detect S. pneumoniae can be applied to different types of clinical samples from patients infected with this bacterium or other related bacteria. Preferably the clinical sample is an isolated biological fluid such as blood, cerebrospinal fluid, saliva or urine.

Abstract: The present invention relates to a compound material consisting of a natural zeolite having calcium as an exchangeable cation, in which hydroxyapatite on a nanometric scale is grown in a controlled manner on the surface thereof; to the method by which said compound material is obtained; and to the use thereof for removing fluoride from water in order to make same drinkable. As a result of the aforementioned special characteristics of hydroxyapatite crystals, said material has a very high intrinsic capacity (based on the weight of hydroxyapatite) for removing fluoride. This capacity, combined with the low cost and ease of access to the materials used for preparing same, and with the straightforward nature of the method, means that said material is the perfect candidate for removing fluoride from water having high levels of this contaminant.

Abstract: The invention relates to the use of the insulin-like growth factor (IGF-1) as a reagent for the early diagnosis and/or prognosis of Alzheimer disease, to a kit comprising IGF-1 and a sedative, and to the use thereof in the early diagnosis and/or prognosis of Alzheimer disease.

Abstract: The invention concerns a method for producing a field effect transistor having a trench gate comprising:—the forming (110) of at least one trench (11, 12, 13) in a semi-conductive substrate (1) having a first type of conductivity, said substrate comprising two opposing faces called front face and rear face,—the primary implantation (120) of ions having a second type of conducitivity so as to implant each trench of the substrate to form an active gate area,—the depositing (160) of a layer of polycrystalline silicon having the second type of conductivity on the implanted active gate area,—the oxidation (160) of the layer of polycrystalline silicon, and—the metallisation (180) of the substrate on the front and rear faces of same in order to form active source and drain areas.

Abstract: The present invention describes a procedure for the production of liquid fuel having a content high in alkanes and low in oxygenated compounds, comprising as a minimum: a first step of alkylation of 2-methylfuran (commonly denominated Sylvan) with a furan alcohol 2 having the formula: (2), wherein R1 is H or an aliphatic or aromatic or heteroaromatic moiety, R2 is H or an aliphatic or aromatic or heteroaromatic moiety, and R3 is H, hydroxymethyl or an aliphatic or aromatic or heteroaromatic moiety, in the presence of a catalyst, a second step of hydrogenation and dehydration of the compound obtained in step 1 in the presence of hydrogen, utilizing suitable hydrogenation and dehydration catalysts.

Abstract: The invention discloses a system for the simultaneous detection and/or quantification of various analytes in a sample or for the simultaneous detection and/or quantification of an analyte in various samples, comprising: a multi-electrode chip (10) comprising an array of microelectrodes (11a, 11b, 11c, 11d); a single-duct cell (20), comprising a groove (21) which accommodates the multi-electrode chip (10) and a duct (22) through which a fluid sample can sequentially flow through each of the microelectrodes (11a, 11b, 11c, 11d) of a multi-electrode chip (10) when the latter is inserted into the groove (21); and a multi-duct cell (30), comprising a groove (31) housing the multi-electrode chip (10) and several independent ducts (32a, 32b, 32c, 32d) through which several samples can pass independently through each electrode (11a, 11b, 11c, 11d) of the multi-electrode chip (10).

Abstract: The invention relates to a method for obtaining membrane vesicles enriched in membrane transport proteins of plant origin, for cosmetic or therapeutic use, which can contain other substances, such as natural bioactive compounds. Preferably, said vesicles are obtained from plants of the Brassicaceae (cruciferae) family. In addition, the invention relates to a method for increasing these proteins of plant origin.

Abstract: The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and/or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia.

Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.

Abstract: The present invention is based on the finding that stearin fats, obtainable by dry or solvent fractionation of sunflower high-stearic and high-oleic oils, optionally with seeding with tempered stearin crystals, have a high solid fat content at temperatures higher than 30° C., even higher than cocoa butter or other high saturated tropical fats with a similar disaturated triacylglycerol content due to the presence of disaturated triacylgiycerols rich in stearic acid, and improved melting point due to the presence of arachidic and behenic acids in these disaturated triacylgiycerols, being at the same time healthier that actual fats made from palm, palm kernel and coconut oils, or hydrogenated and trasesterified vegetable oils.

Abstract: The invention relates to an implant or gel including at least one compound having magnetic functionality, which in turn includes a substrate of at least one enzyme involved in regenerating the extracellular matrix and a plurality of magnetic particles. The invention also relates to a compound having magnetic functionality which includes a substrate of at least one enzyme involved in regenerating the extracellular matrix and a plurality of magnetic particles, preferably with no coating or surface modification, or functionalised with carboxyl groups, for the production of an implant or gel for monitoring an enzyme activity involved in regenerating the extracellular matrix. The substrate is preferably selected from the group that comprises collagen, chondroitin sulphate and hyaluronic acid, and the magnetic particles are superparamagnetic particles.

Abstract: The invention relates to healthy food compositions with a gel or foam texture that have antioxidant properties, are rich in proteins, low-fat, lactose- and casein-free and easy-to-chew, comprising a neutral-flavored egg hydrolysate as a basic ingredient. These compositions are presented as an alternative to sweet and salty dishes using dairy products as a base because they have similar flavor, appearance and texture characteristics. These compositions are also presented as new foods that are particularly indicated for being consumed by people who are lactose intolerant or who have obesity issues.

Abstract: The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins.

Abstract: The present invention relates to a method for covering Atomic Force Microscopy (AFM) tips by depositing a material in the form of nanoparticles with an aggregate source.

Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.